IMBiologics Corp
Company Profile
Business description
IMBiologics Corp is a clinical-stage biopharmaceutical company focused on developing differentiated biologic therapies for immunology and inflammation (I&I) and cancer. The company advances next-generation therapeutics using novel target biology, Modern antibody engineering, and proprietary multivalent platform technologies. It is committed to delivering impactful therapies to patients while creating long-term value through scientific innovation and world-wide collaboration. The group's proprietary IM-OpDECon platform enables the development of novel antibody-based therapeutics with differentiated mechanisms of action. It is advancing a portfolio of new programs, including IMB-101/102, IMB-106, IMB-201, and IMB-402, across autoimmune, inflammatory, and immuno-oncology indications.
Contact
260 Changnyong-daero
11th Floor, Gwanggyo Central Biz Tower
Yeongtong-gu, Iui-dong
Gyeonggi-do
Suwon-si
KORT: +82 3180678170
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
stocks
Microsoft earnings: Azure accelerates, but investment returns remain the test
stocks
Alphabet Earnings: AI Monetisation continues to grow as hardware sales boost results
stocks
After earnings, we raise our Tesla stock Fair Value Estimate. Are shares a buy?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,012.60 | 41.20 | 0.46% |
| CAC 40 | 7,970.00 | 83.04 | 1.05% |
| DAX 40 | 26,039.68 | 335.66 | 1.31% |
| Dow JONES (US) | 52,342.56 | 132.54 | -0.25% |
| FTSE 100 | 10,722.07 | 27.57 | 0.26% |
| HKSE | 22,958.65 | 136.18 | -0.59% |
| NASDAQ | 26,184.72 | 365.13 | -1.38% |
| Nikkei 225 | 64,659.47 | 705.28 | 1.10% |
| NZX 50 Index | 13,736.85 | 26.68 | 0.19% |
| S&P 500 | 7,720.39 | 23.59 | -0.30% |
| S&P/ASX 200 | 8,891.80 | 44.50 | 0.50% |
| SSE Composite Index | 3,651.43 | 30.04 | -0.82% |